OrganonOGN -0.07%71 Net Current Asset Value is $-27.26 as of Mar. 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.54 (Fairly Valued). The stock has 10 warning signs investors should review. Among 613 Drug Manufacturers companies, Organon ranks worse than 163131.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Organon's net current asset value per share for the quarter that ended in Mar. 2026 was $-27.26.
The historical rank and industry rank for Organon's Net Current Asset Value or its related term are showing as below:
OGN's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.53 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Organon (NYSE:OGN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Organon Net Current Asset Value Related Terms
Organon Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Organon's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OGN vs AMRN, SCLX, MIRA: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, Organon's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Organon's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-27.26 mean?
Organon (OGN) has a Net Current Asset Value of $-27.26 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Organon and its competitors. According to the industry distribution chart, Organon ranks #999999 out of 613 companies in the Drug Manufacturers industry.
Is Organon's Net Current Asset Value too high?
Organon's current Net Current Asset Value is $-27.26. Based on the distribution chart, Organon ranks #999999 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Net Current Asset Value compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #999999 out of 613 companies for Net Current Asset Value. This places Organon in the lower half of its industry. The industry median Net Current Asset Value is 5.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.53, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Net Current Asset Value is $-27.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.54, compared to a current price of $13.53 — trading 6.9% below its estimated fair value. The current Net Current Asset Value is $-27.26. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Organon (OGN), the current Net Current Asset Value is $-27.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.53 is trading 6.9% below its estimated GF Value™ of $14.54.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Net Current Asset Value: $-27.26
GF Value™: $14.54 vs. price of $13.53 (6.9% below fair value)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
